Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP419696.RASAdexIItoS5RnUYzlX46AlJ0lEaXkJ0NHyS0g3TGK8M130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP419696.RASAdexIItoS5RnUYzlX46AlJ0lEaXkJ0NHyS0g3TGK8M130_assertion type Assertion NP419696.RASAdexIItoS5RnUYzlX46AlJ0lEaXkJ0NHyS0g3TGK8M130_head.
- NP419696.RASAdexIItoS5RnUYzlX46AlJ0lEaXkJ0NHyS0g3TGK8M130_assertion description "[A total of 50 patients were treated (44 with acute myelogenous leukemia [AML]/myelodysplasia [MDS], 5 with chronic myelogenous leukemia [CML], and 1 with acute lymphocytic leukemia [ALL]), and the drug was well tolerated at all dose levels, with myelosuppression being the major side effect.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP419696.RASAdexIItoS5RnUYzlX46AlJ0lEaXkJ0NHyS0g3TGK8M130_provenance.
- NP419696.RASAdexIItoS5RnUYzlX46AlJ0lEaXkJ0NHyS0g3TGK8M130_assertion evidence source_evidence_literature NP419696.RASAdexIItoS5RnUYzlX46AlJ0lEaXkJ0NHyS0g3TGK8M130_provenance.
- NP419696.RASAdexIItoS5RnUYzlX46AlJ0lEaXkJ0NHyS0g3TGK8M130_assertion SIO_000772 14604977 NP419696.RASAdexIItoS5RnUYzlX46AlJ0lEaXkJ0NHyS0g3TGK8M130_provenance.
- NP419696.RASAdexIItoS5RnUYzlX46AlJ0lEaXkJ0NHyS0g3TGK8M130_assertion wasDerivedFrom befree-2016 NP419696.RASAdexIItoS5RnUYzlX46AlJ0lEaXkJ0NHyS0g3TGK8M130_provenance.
- NP419696.RASAdexIItoS5RnUYzlX46AlJ0lEaXkJ0NHyS0g3TGK8M130_assertion wasGeneratedBy ECO_0000203 NP419696.RASAdexIItoS5RnUYzlX46AlJ0lEaXkJ0NHyS0g3TGK8M130_provenance.